Cleavage of chemokines CCL2 and CXCL10 by matrix metalloproteinases-2 and-9: Implications for chemotaxis

被引:34
作者
Denney, Helen [1 ]
Clench, Malcolm R. [1 ]
Woodroofe, M. Nicola [1 ]
机构
[1] Sheffield Hallam Univ, Fac Hlth & Wellbeing, Biomed Res Ctr, Sheffield S1 1WB, S Yorkshire, England
关键词
Chemokines; Processing; Chemotaxis; CCL2; CXCL10; MMP-2; MMP-9; Matrix metalloproteinase; Multiple sclerosis; Cell migration; GELATINASE-B; POSTTRANSLATIONAL MODIFICATIONS; RECEPTOR; EXPRESSION; IP-10; CXCR3; ANTAGONISTS; ENZYME; RANTES; MCP-2;
D O I
10.1016/j.bbrc.2009.02.164
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteolytic processing of chemokines is a complex process that can result in dramatic effects on their chemotactic activity. Results from gel electrophoresis and mass spectrometry using recombinant CCL2 and CXCL10, incubated with either MMP-2 or -9, indicate that both chemokines are cleaved by the enzymes. N-terminal truncation of four amino acids from CCL2. and four or five residues from CXCL10 occurred, but removal of four residues from the C-terminus of CXCL10 was also observed with both MMPs. The speed of the reaction was chemokine-dependent, with N-terminal processing of CCL2 being complete within 3 h, whereas activity of the MMPs on CXCL10 remained incomplete at 48 h. The effect on the chemotactic potential of N-terminal truncation of CCL2 by MMPs-2 and -9 was investigated using in vitro migration assays. Monocytic cells exhibited a 2-fold reduction in migration to MMP-cleaved CCL2 variants, compared to intact CCL2. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:341 / 347
页数:7
相关论文
共 25 条
[11]   Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1 [J].
McQuibban, GA ;
Butler, GS ;
Gong, JH ;
Bendall, L ;
Power, C ;
Clark-Lewis, I ;
Overall, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (47) :43503-43508
[12]   COMPARATIVE SEQUENCE SPECIFICITIES OF HUMAN 72-KDA AND 92-KDA GELATINASES (TYPE-IV COLLAGENASES) AND PUMP (MATRILYSIN) [J].
NETZELARNETT, S ;
SANG, QX ;
MOORE, WGI ;
NAVRE, M ;
BIRKEDALHANSEN, H ;
VANWART, HE .
BIOCHEMISTRY, 1993, 32 (25) :6427-6432
[13]  
Proost P, 1998, J IMMUNOL, V160, P4034
[14]   Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties [J].
Proost, P ;
Schutyser, E ;
Menten, P ;
Struyf, S ;
Wuyts, A ;
Opdenakker, G ;
Detheux, M ;
Parmentier, M ;
Durinx, C ;
Lambeir, AM ;
Neyts, J ;
Liekens, S ;
Maudgal, PC ;
Billiau, A ;
Van Damme, J .
BLOOD, 2001, 98 (13) :3554-3561
[15]   The clinical potential of chemokine receptor antagonists [J].
Ribeiro, S ;
Horuk, R .
PHARMACOLOGY & THERAPEUTICS, 2005, 107 (01) :44-58
[16]   Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions [J].
Simpson, JE ;
Newcombe, J ;
Cuzner, ML ;
Woodroofe, MN .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 84 (02) :238-249
[17]   Expression of the interferon-γ-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions [J].
Simpson, JE ;
Newcombe, J ;
Cuzner, ML ;
Woodroofe, MN .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2000, 26 (02) :133-142
[18]  
Szabo K., 2004, CLIN APPL IMMUNOL RE, V4, P295, DOI 10.1016/j.cair.2004.02.001
[19]   Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26 dipeptidyl peptidase IV [J].
Van Coillie, E ;
Proost, P ;
Van Aelst, I ;
Struyf, S ;
Polfliet, M ;
De Meester, I ;
Harvey, DJ ;
Van Damme, J ;
Opdenakker, G .
BIOCHEMISTRY, 1998, 37 (36) :12672-12680
[20]   Chemokine-protease interactions in cancer [J].
Van Damme, J ;
Struyf, S ;
Opdenakker, G .
SEMINARS IN CANCER BIOLOGY, 2004, 14 (03) :201-208